Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu
| Autor: | Peter Roselt, Nicholas Zia, Lachlan E. McInnes, Matthew Harris, Sue Jackson, Ellen M van Dam, Rodney J. Hicks, Carleen Cullinane, Benjamin Blyth, Paul S. Donnelly |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
business.industry
urologic and male genital diseases medicine.disease Bivalent (genetics) 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Antigen Cell culture 030220 oncology & carcinogenesis Radionuclide therapy Cancer research Glutamate carboxypeptidase II Medicine Radiology Nuclear Medicine and imaging Tumor growth business After treatment |
| Zdroj: | Journal of Nuclear Medicine. 62:829-832 |
| ISSN: | 2159-662X 0161-5505 |
| Popis: | Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion:67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|